Pulmatrix (PULM) Operating Leases (2019 - 2024)

Pulmatrix (PULM) posted Operating Leases of $8.2 million for Q1 2024, down 1.18% sequentially from $8.3 million in Q4 2023.

Pulmatrix (PULM) Operating Leases (2019 - 2024) Analysis & Trends

Pulmatrix has reported Operating Leases for 6 years, with the latest figure at $8.2 million in Q1 2024.

Quarterly Operating Leases changed N/A year-over-year to $8.2 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $8.2 million (changed N/A YoY) and the FY2023 annual result came in at $8.3 million, changed N/A from the prior year.
Operating Leases slipped to $8.2 million in Q1 2024 per PULM's latest filing, from $8.3 million in the prior quarter.
Over five years, Operating Leases peaked at $8.4 million in Q3 2023 and troughed at $430000.0 in Q1 2022.
A 5-year average of $2.9 million and a median of $1.3 million in 2021 frame the typical range for Operating Leases.
The sharpest annual moves came in 2021 and 2022: Operating Leases surged 186.69% in 2021, then slumped 70.65% in 2022.
Over 5 years, Operating Leases stood at $608000.0 in 2020, then jumped by 40.95% to $857000.0 in 2021, then slumped by 49.82% to $430000.0 in 2022, then surged by 1836.51% to $8.3 million in 2023, then slipped by 1.18% to $8.2 million in 2024.
According to Business Quant data, Operating Leases over the past three periods registered $8.2 million, $8.3 million, and $8.4 million for Q1 2024, Q4 2023, and Q3 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Pulmatrix	5.46 Mn	5.46 Mn	-

Download Data